Episode 44 - Genome-wide meta-analysis in lichen sclerosus

In this episode of BJD Talks, Sam and Meera discuss the article ‘Genome-wide meta-analysis in lichen sclerosus identifies 14 genomic risk loci’ by Dand et al. The full article can be accessed at https://doi.org/10.1093/bjd/ljag088

*This podcast was generated by an AI tool created by 67Bricks for the British Association of Dermatologists*

Transcript

SPEAKER_01 0:00

Welcome to BJD Talks, the official podcast of the BJD. I'm Sam.

SPEAKER_00 0:04

And I'm Mira. In this episode, we will be discussing the article by Nick Dand et al. Genome-wide meta-analysis in lichen sclerosis identifies 14 genomic risk lochae from March 2026 and included in the July 2026 issue.

SPEAKER_01 0:21

This paper might be one of the most comprehensive genetic studies on lichen sclerosis, or LS to date. It's a chronic inflammatory condition, primarily affecting genital skin in both sexes. It causes significant discomfort, itching, scarring, and in some cases, even malignant transformation.

SPEAKER_00 0:41

Indeed, despite familial patterns and suspected autoimmune triggers, the genetic aspect of LS remains underexplored. This study uses data from over 7,600 cases across European Biobanks, UK Biobank, FinGen, and the Trondelag Health Study. 14 genetic risk loci were identified, particularly the MHC class II allele, HLADRB 11201.

SPEAKER_01 1:08

That allele was strongly linked with susceptibility in both sexes, with a two and a half-fold increased risk. However, LS is more prevalent in women who also exhibit higher rates of autoimmune comorbidities and extragenital involvement. There's clearly a sex-specific genetic dynamic at play.

SPEAKER_00 1:26

Exactly. Sex-stratified genome-wide studies revealed 12 risk loci unique to females. One variant in the IGFLR1 gene, for example, was protective in women, with an odds ratio of 0.71. It underscores potential differences in pathogenesis between sexes.

SPEAKER_01 1:45

What's compelling is that they complemented these findings by aligning their results with functional data, revealing dysregulated immune and metabolic pathways. Genes like CD247, IL2RB, and ALDH2 emerged as key players. Clinically, these pathways could serve as potential therapeutic targets.

SPEAKER_00 2:15

This locus overlaps with conditions such as vitiligo and coronary artery disease, indicating shared pathomechanisms between LS and systemic diseases.

SPEAKER_01 2:26

The team also highlighted shared genetic influences between sexes, though the effects were diluted in men. With fewer male patients, only 970 compared to 6,681 females, it's possible that male-specific mechanisms remain underexplored.

SPEAKER_00 2:44

True, Sam. A further limitation is the study's reliance on European ancestry data, limiting wider applicability. Yet the statistical methods used, such as fine mapping and colloquialization studies, were robust and provided insights into causal variance and gene expression in skin and T cells.

SPEAKER_01 3:05

The translational value is significant. It's not just about identifying genes but understanding LS as a genetically complex immune-mediated disease. These findings paved the way for improved diagnostics and targeted treatments.

SPEAKER_00 3:18

Absolutely. Intervening in pathways involving IgFLR1 or modulating CD247 expression, if it can be proven safe to do so, could transform LS management. For a condition so impactful on quality of life, this level of precision medicine would be game-changing.

SPEAKER_01 3:36

Before we wrap, the takeaway here is clear. LS is not merely a localized skin disorder, but a systemic inflammatory condition. With genetic roots, we are only beginning to unravel.

SPEAKER_00 3:48

Nicely put, Sam. This study showcases the leaps being made in dermatogenomics. With more diverse cohorts and focused functional studies, the future does look promising for LS patients.

SPEAKER_01 3:59

And on that hopeful note, that's all for this episode of BJD Talks. Thanks for listening, and don't forget to join us next time for more insights into dermatology research.

SPEAKER_00 4:09

Take care, everyone, and as always, stay curious.